ストックスクリーナーアプリを入手
38.24
6.94%
-2.85
アフターアワーズ：
38.20
-0.04
-0.10%
前日終値:
$41.09
開ける：
$41.1
24時間の取引高:
814.69K
Relative Volume:
1.07
時価総額：
$1.86B
収益：
$140.49M
当期純損益:
$-153.49M
株価収益率:
-13.88
EPS:
-2.7551
ネットキャッシュフロー:
$-175.90M
1週間 パフォーマンス:
-6.66%
1か月 パフォーマンス:
+3.91%
6か月 パフォーマンス:
+95.00%
1年 パフォーマンス:
+100.63%
1日の値動き範囲:
$38.01
$41.10
1週間の範囲:
$38.01
$42.15
52週間の値動き範囲:
$15.86
$43.93
Urogen Pharma Ltd Stock (URGN) Company Profile
Compare URGN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
38.24 | 2.02B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Jefferies | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-06-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-19 | 再開されました | Ladenburg Thalmann | Buy |
| 2024-08-22 | 開始されました | Guggenheim | Buy |
| 2023-02-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-27 | 開始されました | Berenberg | Buy |
| 2020-04-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | National Securities | Neutral |
| 2019-05-30 | 開始されました | JP Morgan | Neutral |
| 2019-05-29 | 開始されました | Goldman | Neutral |
| 2019-01-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-04-04 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-11-15 | 繰り返されました | Oppenheimer | Outperform |
| 2017-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
すべてを表示
Urogen Pharma Ltd (URGN) 最新ニュース
Return on invested capital % of UroGen Pharma Ltd. – HAM:UR8 - TradingView
EBITDA of UroGen Pharma Ltd. – HAM:UR8 - TradingView
Cost of goods sold of UroGen Pharma Ltd. – HAM:UR8 - TradingView
Operating expenses (excl. COGS) of UroGen Pharma Ltd. – HAM:UR8 - TradingView
UroGen Pharma Ltd. Revenue Breakdown – HAM:UR8 - TradingView
Urogen Pharma Ltd (URGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Urogen Pharma Ltd (URGN) Institutional Confidence - TradingKey
Price to earnings forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to earnings forward of UroGen Pharma Ltd. – FWB:UR8 - TradingView
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
URGN stock trades steady as UroGen revenue grows and pipeline advances - Ad-hoc-news.de
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders - simplywall.st
Enterprise value to revenue forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to sales forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN) - Seeking Alpha
Price to earnings forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma (URGN) AGM 2026 Summary - Quartr
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout | AI
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow - simplywall.st
Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com - Investing.com South Africa
ETFs Investing in UroGen Pharma Ltd. Stocks - TradingView
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 - Barchart.com
Urogen Pharma stock hits 52-week high at 41.45 USD - Investing.com
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news - Investing.com UK
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
URGN Maintained by Oppenheimer -- Price Target Raised to $50 - GuruFocus
Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook - Investing.com Canada
UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment - GuruFocus
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 - 富途牛牛
UroGen receives US patent allowance for bladder cancer treatment - Investing.com UK
Should I Buy URGN (UroGen Pharma Ltd.) | AI Analysis, Technical & News Insights - Kavout | AI
UroGen receives US patent allowance for bladder cancer treatment By Investing.com - Investing.com Nigeria
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - The Manila Times
UroGen Receives New U.S. Patent Allowance Expected to - GlobeNewswire
UroGen patent allowance covers bladder cancer care without tumor resection - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - BioBuzz
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com Nigeria
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - Sahm
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares By Investing.com - Investing.com Australia
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com India
Urogen Pharma Ltd (URGN) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):